Daniel E. Furst

49.4k total citations · 2 hit papers
382 papers, 17.5k citations indexed

About

Daniel E. Furst is a scholar working on Pathology and Forensic Medicine, Rheumatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Daniel E. Furst has authored 382 papers receiving a total of 17.5k indexed citations (citations by other indexed papers that have themselves been cited), including 208 papers in Pathology and Forensic Medicine, 133 papers in Rheumatology and 100 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Daniel E. Furst's work include Systemic Sclerosis and Related Diseases (188 papers), Rheumatoid Arthritis Research and Therapies (104 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (87 papers). Daniel E. Furst is often cited by papers focused on Systemic Sclerosis and Related Diseases (188 papers), Rheumatoid Arthritis Research and Therapies (104 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (87 papers). Daniel E. Furst collaborates with scholars based in United States, Italy and United Kingdom. Daniel E. Furst's co-authors include Dinesh Khanna, Philip J. Clements, Steven Fischkoff, Elliot Chartash, Edward Keystone, C. Birbara, Michael H. Weisman, Michael E. Weinblatt, Donald P. Tashkin and Larry W. Moreland and has published in prestigious journals such as The Lancet, JAMA and Journal of Clinical Investigation.

In The Last Decade

Daniel E. Furst

372 papers receiving 16.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial

2003 1.4k citations Michael E. Weinblatt, Daniel E. Furst et al. profile →
Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis

2017 320 citations Dinesh Khanna, Daniel E. Furst et al. Journal of Scleroderma and Related Disorders profile →

Peers

Countries citing papers authored by Daniel E. Furst

Since Specialization

Citations

This map shows the geographic impact of Daniel E. Furst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel E. Furst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel E. Furst more than expected).

Fields of papers citing papers by Daniel E. Furst

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel E. Furst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel E. Furst. The network helps show where Daniel E. Furst may publish in the future.

Co-authorship network of co-authors of Daniel E. Furst

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel E. Furst. A scholar is included among the top collaborators of Daniel E. Furst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel E. Furst. Daniel E. Furst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	What Matters in Psoriatic Arthritis: A Comparison of Patient and Clinician Perspectives 2025 ·ACR Open Rheumatology ·Philip J. Mease, M. Elaine Husni, Evan Siegel, Daniel E. Furst, M. McIlraith, Vibeke Strand, M. Cameron Hay	2
2	The Rising Challenge of Poor Health Literacy of Patients with Systemic Sclerosis: Preliminary Data Identify Important Unmet Needs in an Italian Cohort 2024 ·SHILAP Revista de lepidopterología ·Khadija El Aoufy, (unknown), Paolo Iovino, Stefano Bambi, Chiara Lorini, Guglielmo Bonaccorsi, Ilaria Galetti, (unknown), (unknown), (unknown), (unknown), Serena Guiducci, Daniel E. Furst, Marco Matucci‐Cerinic, Laura Rasero, Silvia Bellando-Randone	2
3	Myeloablation Followed by Hematopoietic Stem Cell Transplantation and Long‐Term Normalization of Systemic Sclerosis Molecular Signatures 2024 ·Arthritis & Rheumatology ·Nancy Wareing, Xuan Wang, (unknown), Ellen Goldmuntz, (unknown), Peter A. McSweeney, Daniel E. Furst, Richard A. Nash, Leslie J. Crofford, Beverly Welch, Ashley Pinckney, Maureen D. Mayes, Keith M. Sullivan, Shervin Assassi	3
4	Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohort 2023 ·Lara D. Veeken ·(unknown), Dinesh Khanna, Celia J. F. Lin, Daniel E. Furst, Ganesh Raghu, Fernando J. Martínez, Mauro Zucchetto, Suiyuan Huang, (unknown), Svetlana I. Nihtyanova, Christopher P. Denton	16
5	Economic and Health Care Resource Use Burden of Systemic Sclerosis 2023 ·ACR Open Rheumatology ·Dinesh Khanna, Daniel E. Furst, (unknown), (unknown), Yuan Yuan, (unknown), (unknown), Farah Mahmoud Ali, Brian LaMoreaux, (unknown)	2
6	A 24‐Week, Phase IIa, Randomized, Double‐Blind, Placebo‐Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis 2023 ·Arthritis & Rheumatology ·Dinesh Khanna, Christopher P. Denton, Daniel E. Furst, Maureen D. Mayes, Marco Matucci‐Cerinic, Vanessa Smith, (unknown), Paul Ford, Yasmina Bauer, Matthew J. Randall, Mitra Ebrahimpoor, László Kupcsik, (unknown), (unknown), (unknown), (unknown), Philippe Pujuguet, Sohail Ahmed	15
7	Adipose‐Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial 2022 ·Arthritis & Rheumatology ·Dinesh Khanna, Paul H. Caldron, Richard W. Martin, Suzanne Kafaja, Robert Spiera, (unknown), Ankoor R. Shah, Vivien Hsu, John Ervin, Robert W. Simms, Robyn T. Domsic, Virginia Steen, Laura K. Hummers, Chris T. Derk, Maureen D. Mayes, Soumya Chatterjee, John Varga, Steven Kesten, John K. Fraser, Daniel E. Furst	20
8	Myeloablative autologous haematopoietic stem cell transplantation resets the B cell repertoire to a more naïve state in patients with systemic sclerosis 2022 ·Annals of the Rheumatic Diseases ·Julia Z. Adamska, Amin Zia, Michelle S. Bloom, Leslie J. Crofford, Daniel E. Furst, Ellen Goldmuntz, Lynette Keyes-Elstein, Maureen D. Mayes, Peter A. McSweeney, Richard A. Nash, Ashley Pinckney, Beverly Welch, (unknown), Keith M. Sullivan, William H. Robinson	11
9	Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working group 2021 ·Seminars in Arthritis and Rheumatism ·(unknown), Thasia Woodworth, Niti Goel, John P. A. Ioannidis, Peter Tugwell, (unknown), Paula Williamson, Caroline B. Terwee, María E. Suarez‐Almazor, Vibeke Strand, Amye Leong, Philip G. Conaghan, Maarten Boers, Beverley Shea, Peter Brooks, Lee S. Simon, Daniel E. Furst, Robin Christensen	2
10	Performance of 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in a paediatric population—a multicentre study 2021 ·Lara D. Veeken ·Yoel Levinsky, (unknown), (unknown), Ori Goldberg, Oded Scheuerman, (unknown), Irit Tirosh, (unknown), Daniel E. Furst, Liora Harel, Gil Amarilyo	15
11	Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo‐Controlled Trial in Adults With Systemic Sclerosis 2020 ·Arthritis & Rheumatology ·Robert Spiera, Laura K. Hummers, Leland W.K. Chung, Tracy Frech, Robyn T. Domsic, Vivien Hsu, Daniel E. Furst, Jessica Gordon, Maureen D. Mayes, Robert W. Simms, Robert Lafyatis, Viktor Martyanov, Tammara Wood, Michael L. Whitfield, S. Constantine, Elizabeth Lee, Nancy Dgetluck, Barbara White	72
12	Population characteristics as important contextual factors in rheumatological trials: an exploratory meta-epidemiological study from an OMERACT Working Group 2020 ·Annals of the Rheumatic Diseases ·Sabrina Mai Nielsen, (unknown), Torkell Ellingsen, Beverley Shea, George A. Wells, Vivian Welch, Daniel E. Furst, Maarten de Wit, Marieke Voshaar, Carsten Bogh Juhl, Maarten Boers, Reuben Escorpizo, Thasia Woodworth, Annelies Boonen, Henning Bliddal, Lyn March, Peter Tugwell, Robin Christensen	4
13	Coping profiles and health outcomes among individuals with systemic sclerosis: A latent profile analysis approach 2020 ·Journal of Scleroderma and Related Disorders ·(unknown), Scott C. Roesch, Philip J. Clements, Daniel E. Furst, Michael H. Weisman, Vanessa L. Malcarne	4
14	Data‐Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women’s Rheumatoid Arthritis Sequential Study Registry 2020 ·Arthritis Care & Research ·Jeffrey R. Curtis, Michael E. Weinblatt, Kenneth G. Saag, Vivian P. Bykerk, Daniel E. Furst, Stefano Fiore, Gregory St John, Toshio Kimura, (unknown), Clifton O. Bingham, Grace C. Wright, Martin Bergman, (unknown), Christina Charles‐Schoeman, Nancy A. Shadick	13
15	Factor structure and convergent validity of the Derriford Appearance Scale-24 using standard scoring versus treating ‘not applicable’ responses as missing data: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study 2018 ·BMJ Open ·Erin L. Merz, Linda Kwakkenbos, (unknown), Shadi Gholizadeh, Sarah D. Mills, Rina S. Fox, Lisa R. Jewett, Heidi Williamson, Diana Harcourt, Shervin Assassi, Daniel E. Furst, Karen Gottesman, Maureen D. Mayes, Timothy Moss, Brett D. Thombs, Vanessa L. Malcarne	8
16	Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study 2016 ·Annals of the Rheumatic Diseases ·Paul Emery, Clifton O. Bingham, Gerd R Burmester, Vivian P. Bykerk, Daniel E. Furst, Xavier Mariette, Désirée van der Heijde, Ronald van Vollenhoven, Catherine Arendt, Irina Mountian, O. Purcaru, Daljit Tatla, Michael E. Weinblatt, (unknown)	72
17	Efficacy and Safety of Mycophenolate (MMF) Vs Oral Cyclophosphamide (CYC) for Treatment of Scleroderma-Interstitial Lung Disease (Ssc-ILD): Results of Scleroderma Lung Study II 2015 ·CHEST Journal ·Donald P. Tashkin, Michael D. Roth, Philip J. Clements, Daniel E. Furst, Dinesh Khanna, Jonathan Goldin, Eric C. Kleerup, (unknown), Chi‐Hong Tseng, Robert Elashoff	4
18	Interpreting trial results following use of different intention-to-treat approaches for preventing attrition bias: a meta-epidemiological study protocol 2014 ·BMJ Open ·(unknown), Simon Tarp, Daniel E. Furst, Christian Gluud, Joseph Beyene, Bjarke Brandt Hansen, Henning Bliddal, Robin Christensen	18
19	Publication Outcomes of Abstracts Presented at an American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting 2012 ·Arthritis Care & Research ·Gil Amarilyo, Jennifer M. P. Woo, Daniel E. Furst, (unknown), (unknown), (unknown), D. Stott Parker, Deborah McCurdy	14
20	pDCs and IL-4+ T-cells in scleroderma as novel targets of imatinib mesylate (44.18) 2011 ·The Journal of Immunology ·Anagha Divekar, Dinesh Khanna, Fereidoun Abtin, Paul Maranian, Rajeev Saggar, Rajan Saggar, Daniel E. Furst, Ram Raj Singh	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact